Mobile

A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transplant ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-001102-31

A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transplant patients

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The objective of this study is to obtain information on the pharmacokinetics of tacrolimus when used in combination with everolimus in stable kidney transplant patients.

Critère d'inclusion

  • Stable, adult kidney transplant recipients (≥ 6 months post transplant) who are currently treated with Prograf®/MMF(CellCept®) or Prograf®/Mycophenolate Sodium(Myfortic®) with or without steroids will be enrolled

Liens